Excerpts

As shown in Figure 2 B, average intracellular ROS levels in each cell line exhibited an increasing trend with longer NIPP treatment durations, suggesting that ROS likely plays a significant role in mediating subsequent cellular responses. 3.4.

Both primary tumors and liver METs showed a trend toward a higher frequency of NETs compared with normal samples; however, these differences were not statistically significant.

Observational studies showed a significantly reduced risk of rebleeding with anticoagulation (OR 0.15, 95% CI 0.04–0.52), while randomized controlled trials demonstrated a nonsignificant trend in the same direction (OR 0.84, 95% CI 0.31–2.32) [ 115 ].

60.7%, p = 0.049), while BRCA mutations showed a favorable trend.

These findings suggest that supportive care needs are similar across dosing strategies, with a possible trend toward more treatment interruptions in the fixed-dose group.

Conclusions: The addition of CDK4/6i to ET improves iDFS and shows a favorable trend in DRFS in early-stage HR+/HER2− breast cancer, highlighting the need for longer follow-up to clarify their long-term benefit. early-stage HR+/HER2− breast cancer CDK4/6 inhibitors endocrine therapy adjuvant therapy meta-analysis invasive disease-free survival abemaciclib ribociclib palbociclib Thi

The key outcomes of this meta-analysis indicate that CDK4/6 inhibitors significantly improve iDFS, while a clear trend toward benefit is also observed in DRFS, suggesting a potentially clinically meaningful effect that has not yet reached statistical significance.

Patients who received immunotherapy and had an ECOG-PS of 0 ( n = 73) showed a trend towards a worse mOS in the early TG (15 m; 95% CI = 4.32–25.68 vs. 20 m; 95% CI = 9.05–31.00).

Finally, a study using data from the U.S.–Canada Children’s Oncology Group (COG) showed a marginally significant association between residential exposure to parental insecticide use and the use of professional lawn/landscape services and unilateral retinoblastoma (99 cases, OR 2.8; 1.1–6.7 and OR 2.8; 1.0–8.2, respectively) [ 64 ].

Although statistical significance was not reached ( p = 0.059), likely due to the small sample size, imatinib showed a trend toward improved TTP after initiation of therapy when compared with the BRACHY-001 trial vaccines.

A marginally statistically significant difference was also observed in the percentage of tumour volume reduction and RECIST response rate.

Although this association was marginally non-significant in multivariate analysis, combining SARIFA with LVI in a composite variable improved predictive accuracy.

Unsupervised hierarchical clustering based on these epifactor expressions also showed a trend toward the reclassification of molecular subtypes in the Williamson dataset ( Figure 4 H).

Unsurprisingly, in the overall cohort of 255 patients, no statistically significant differences were observed in disease-free survival (DFS) (HR 0.71, 95% CI 0.48–1.05, p = 0.084) or overall survival (OS) (HR 0.69, 95% CI 0.48–1.05, p = 0.096), although a favorable trend was noted in the surgical arm, suggesting the possibility of a type II error.

However, in the recently reported TRUST trial [ 29 ], upfront surgery showed significantly improved median PFS (22.2 months) and showed a trend toward longer overall survival (OS) (54 months), compared to neoadjuvant chemotherapy, followed by interval cytoreductive surgery (19.7 months and 48.3 months, respectively.

Device availability is currently restricted, and initial capital investment may be significant.

Similarly, analysis of clinical data from The Cancer Genome Atlas-Breast Invasive Carcinoma (TCGA-BRCA) cohort reveals a positive correlation between WWOX expression and E-cadherin levels, alongside a negative trend with fibronectin levels in TNBC samples.

For the five top selected radiomic features, we observed that they had a clear trend of either increase or decrease based on the risk of lung cancer development ( Figure 2 b), as stratified in 4 groups including the “<1-year” group for those diagnosed within a year, the “1–3 year” group for patients diagnosed between one and three years, and for “>3-year” and “>7-year” groups for individuals diagnosed after more than three and seven years, respectively.

Regarding prognostic impact, our data show a favorable trend in overall survival for patients who received targeted therapies guided by ctDNA results.

reported that G12C and G12V were predictive of poor OS in patients with recurrent and metastatic disease, and G12A also showed a trend toward poor OS [ 15 ].

Nevertheless, multifocality is often perceived as a useful parameter for guiding intensified TC management, particularly in light of reports indicating an increasing trend in the number of tumor foci in recent years [ 14 , 15 , 41 , 48 ]. 4.4.

While most institutions showed a trend towards risk reduction (HR < 1.00), the result from DCMC (HR, 0.67; 95% CI, 0.47–0.95) was individually significant.

These factors decrease the generalizability of results and do not account for the placebo effect, which may be significant in cancer-related symptom research [ 48 ].

Third, although patients under 60 years of age showed a trend toward higher rates of stage IV disease and distant metastasis at diagnosis, these differences did not reach statistical significance.

For instance, in lung adenocarcinomas, this loss of size control may be significant [ 54 ].